Drug intelligence / Profile preview

letrozole + palbociclib + venetoclax

Development stage: Unknown
Lead developer: Peter MacCallum Cancer Centre
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of letrozole (an aromatase inhibitor), palbociclib (a CDK4/6 inhibitor), and venetoclax (a BCL-2 inhibitor) being investigated for the treatment of estrogen receptor (ER) and BCL-2 positive locally advanced or metastatic breast cancer. Pre-clinical findings indicate that venetoclax augments tumor response to palbociclib by triggering apoptosis, including in senescent cells.

Targets

BCL-2 (BCL-2 family)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on letrozole + palbociclib + venetoclax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on letrozole + palbociclib + venetoclax.

Explore the full profile